NASDAQ:BMRN - BioMarin Pharmaceutical Stock Price, Price Target & More

$81.53 +0.40 (+0.49 %)

(As of 04/25/2018 04:00 PM ET)

Previous Close$81.53

Today's Range$80.3050 - $82.16

52-Week Range$75.81 - $100.51

Volume1.25 million shs

Average Volume1.34 million shs

Market Capitalization$14.45 billion

P/E Ratio-121.69

Dividend YieldN/A

Beta1.69

About BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome. The company's commercial products also comprise Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria; vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans; valoctocogene roxaparvovec, an AAV5 vector and factor VIII gene therapy drug development candidate for the treatment of severe hemophilia A; BMN 250, an investigational enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B or mucopolysaccharidosis type IIIB; and BMN 290, a selective chromatin modulation therapy for the treatment of Friedreich's ataxia. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration agreements with Sarepta Therapeutics and Genzyme Corporation; and a license agreement with Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.

Receive BMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:BMRN

CUSIP09061G10

Webwww.bmrn.com

Phone415-506-6700

Debt

Debt-to-Equity Ratio0.29%

Current Ratio2.70%

Quick Ratio2.12%

Price-To-Earnings

Trailing P/E Ratio-121.69

Forward P/E Ratio-509.56

P/E GrowthN/A

Sales & Book Value

Annual Sales$1.31 billion

Price / Sales10.93

Cash FlowN/A

Price / CashN/A

Book Value$15.99 per share

Price / Book5.10

Profitability

EPS (Most Recent Fiscal Year)($0.67)

Net Income$-117,040,000.00

Net Margins-8.91%

Return on Equity-3.18%

Return on Assets-2.07%

Miscellaneous

Employees2,581

Outstanding Shares176,070,000

How to Become a New Pot Stock Millionaire

BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical (NASDAQ:BMRN) announced its quarterly earnings results on Thursday, February, 22nd. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.06. The biotechnology company earned $358.31 million during the quarter, compared to analysts' expectations of $346.24 million. BioMarin Pharmaceutical had a negative net margin of 8.91% and a negative return on equity of 3.18%. View BioMarin Pharmaceutical's Earnings History.

When is BioMarin Pharmaceutical's next earnings date?

BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, April, 25th 2018. View Earnings Estimates for BioMarin Pharmaceutical.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical issued an update on its FY18 earnings guidance on Wednesday, April, 25th. The company provided earnings per share guidance of $0.57-0.79 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.70. The company issued revenue guidance of $1.47-1.53 billion, compared to the consensus revenue estimate of $1.49 billion.

What price target have analysts set for BMRN?

19 equities research analysts have issued 12 month target prices for BioMarin Pharmaceutical's shares. Their forecasts range from $89.00 to $150.00. On average, they anticipate BioMarin Pharmaceutical's stock price to reach $113.8421 in the next year. View Analyst Ratings for BioMarin Pharmaceutical.

What are Wall Street analysts saying about BioMarin Pharmaceutical stock?

Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:

1. According to Zacks Investment Research, "BioMarin’s key orphan disease drugs – Vimizim and Kuvan – continue to do well, backed by strong underlying patient demand trends. BioMarin expects sustained growth in both the drugs. Brineura’s earlier-than-expected approval was also a huge boost for BioMarin. Its impressive rare-disease pipeline is also progressing well with approval for pegvaliase expected in 2018. However, BioMarin has suffered a few regulatory setbacks related to its pipeline candidates in the past. Further development setbacks can have a negative impact on the stock. Also, Naglazyme and Vimzin revenues vary on a quarterly basis primarily due to infrequent ordering patterns from some countries, mainly Brazil. The stock has also underperformed the industry in the past year. Earnings estimates have increased ahead of the company’s Q1 earnings release. The company has a mixed record of earnings surprises in recent quarters." (4/25/2018)
2. JPMorgan Chase analysts commented, "BMRN’s 4Q print was largely in-line; the company also provided 2018 guidance that bracketed consensus revenue expectations. There was some incremental color on regulatory (pegvaliase) and commercial (Brineura/pegvaliase) progress / expectations for emerging products. Importantly, the pipeline continues on track, and 2019 looks to be a critical year on that front. We anticipate interest in BMRN will increase materially as we eventually get closer to the pivotal data for val rox and vosoritide. Reiterate OW." (2/25/2018)
3. Cowen Inc analysts commented, "New data include 52 wk follow-up on all patients at BMN270’s 6e13 vg/kg dose, and." (7/11/2017)

Who are some of BioMarin Pharmaceutical's key competitors?

Some companies that are related to BioMarin Pharmaceutical include Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY), Regeneron (REGN), Astellas Pharma (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), Grifols (GRFS), Ono Pharmaceutical (OPHLF) and Nektar Therapeutics (NKTR).

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the folowing people:

Mr. Jean-Jacques Bienaimé, Chairman & CEO (Age 65)
Mr. Daniel K. Spiegelman, Exec. VP & CFO (Age 59)
Dr. Robert A. Baffi Ph.D., MBA, Exec. VP of Technical Operations (Age 63)
Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 56)
Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 60)

Has BioMarin Pharmaceutical been receiving favorable news coverage?

Media headlines about BMRN stock have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BioMarin Pharmaceutical earned a news sentiment score of 0.18 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.03 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional shareholders include PRUDENTIAL FINANCIAL INC (6.80%) and PRIMECAP MANAGEMENT COMPANY (5.86%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $81.53.

How big of a company is BioMarin Pharmaceutical?

BioMarin Pharmaceutical has a market capitalization of $14.45 billion and generates $1.31 billion in revenue each year. The biotechnology company earns $-117,040,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis. BioMarin Pharmaceutical employs 2,581 workers across the globe.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected]

MarketBeat Community Rating for BioMarin Pharmaceutical (BMRN)

Community Ranking:		3.4 out of 5 ( )
Outperform Votes:		948 (Vote Outperform)
Underperform Votes:		463 (Vote Underperform)
Total Votes:		1,411

MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote "Outperform" if you believe BMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.

BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

19 Wall Street analysts have issued ratings and price targets for BioMarin Pharmaceutical in the last 12 months. Their average twelve-month price target is $113.8421, suggesting that the stock has a possible upside of 39.63%. The high price target for BMRN is $150.00 and the low price target for BMRN is $89.00. There are currently 4 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.84	2.84	2.77	2.70
Ratings Breakdown:	0 Sell Rating(s) 4 Hold Rating(s) 14 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 14 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 6 Hold Rating(s) 15 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 7 Hold Rating(s) 16 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$113.8421	$113.8421	$112.95	$112.2727
Price Target Upside:	39.63% upside	35.83% upside	22.25% upside	36.07% upside

BioMarin Pharmaceutical (NASDAQ:BMRN) Consensus Price Target History

Price Target History for BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical (NASDAQ:BMRN) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/29/2018	Credit Suisse Group	Reiterated Rating	Buy	$116.00	Medium
3/12/2018	Wedbush	Reiterated Rating	Outperform	$110.00	Medium
2/27/2018	Royal Bank of Canada	Reiterated Rating	Hold	$94.00	Medium
2/25/2018	JPMorgan Chase	Reiterated Rating	Buy		Low
2/23/2018	Morgan Stanley	Lower Price Target	Overweight -> Overweight	$115.00 -> $112.00	Medium
2/23/2018	Stifel Nicolaus	Lower Price Target	Buy -> Buy	$105.00 -> $102.00	High
2/23/2018	Leerink Swann	Lower Price Target	Outperform -> Outperform	$142.00 -> $132.00	High
2/23/2018	BMO Capital Markets	Reiterated Rating	Outperform -> Outperform	$119.00 -> $125.00	High
2/23/2018	Deutsche Bank	Set Price Target	Buy -> Buy	$119.00 -> $124.00	High
1/18/2018	Piper Jaffray	Reiterated Rating	Buy	$114.00	Low
12/15/2017	Goldman Sachs	Upgrade	Buy -> Conviction-Buy		High
12/11/2017	SunTrust Banks	Boost Price Target	Buy	$130.00	High
9/26/2017	Jefferies Group	Reiterated Rating	Buy	$116.00	Low
8/31/2017	Citigroup	Initiated Coverage	Buy -> Buy	$98.00	Medium
8/16/2017	Evercore ISI	Initiated Coverage	Outperform -> Outperform	$100.00	High
8/4/2017	Cowen	Reiterated Rating	Buy		Low
8/3/2017	UBS	Reiterated Rating	Neutral	$92.00 -> $93.00	Low
7/27/2017	Sanford C. Bernstein	Initiated Coverage	Market Perform	$89.00	High
7/22/2017	Barclays	Reiterated Rating	Equal Weight	$105.00 -> $100.00	Low
3/1/2017	Instinet	Initiated Coverage	Neutral -> Neutral	$93.00	N/A
3/1/2017	Nomura	Initiated Coverage	Neutral		N/A
2/10/2017	Gabelli	Reiterated Rating	Buy		N/A
1/9/2017	Robert W. Baird	Set Price Target	Buy	$115.00	N/A
7/28/2016	William Blair	Set Price Target	Buy	$116.00	N/A
6/20/2016	Oppenheimer	Reiterated Rating	Market Perform	$99.00	N/A

(Data available from 4/25/2016 forward)

BioMarin Pharmaceutical (NASDAQ:BMRN) Earnings History and Estimates Chart

Earnings by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical (NASDAQ:BMRN) Earnings Estimates

2018 EPS Consensus Estimate: ($0.59)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	4	($0.26)	$0.17	($0.11)
Q2 2018	3	($0.19)	($0.16)	($0.18)
Q3 2018	4	($0.21)	($0.10)	($0.15)
Q4 2018	3	($0.20)	($0.04)	($0.15)

BioMarin Pharmaceutical (NASDAQ BMRN) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/25/2018	Q1 2018	($0.10)	$0.12	$348.73 million	$373.45 million		N/A
2/22/2018	Q4 2017	($0.24)	($0.30)	$346.24 million	$358.31 million	View	N/A
10/26/2017	Q3 2017	($0.13)	($0.07)	$347.38 million	$334.18 million	View	N/A
8/2/2017	Q2 2017	($0.22)	($0.21)	$311.41 million	$317.50 million	View	Listen
5/4/2017	Q1 2017	($0.30)	$0.03	$292.58 million	$303.70 million	View	Listen
2/23/2017	Q416	($0.38)	($0.53)	$296.54 million	$300.00 million	View	N/A
10/27/2016	Q316	($0.39)	($0.13)	$289.70 million	$279.90 million	View	Listen
8/4/2016	Q216	($0.52)	($2.61)	$278.75 million	$300.10 million	View	N/A
4/28/2016	Q116	($0.85)	($0.53)	$240.21 million	$236.70 million	View	Listen
2/25/2016	Q415	$0.67	$0.39	$224.14 million	$227.90 million	View	Listen
10/29/2015	Q315	($0.65)	($0.60)	$216.32 million	$208.90 million	View	Listen
8/3/2015	Q215	($0.53)	($0.22)	$218.16 million	$250.50 million	View	N/A
4/30/2015	Q1	($0.53)	($0.25)	$204.58 million	$203.26 million	View	N/A
2/25/2015	Q414	($0.59)	($0.30)	$189.01 million	$230.90 million	View	N/A
10/23/2014	Q314	($0.22)	($0.16)	$206.00 million	$176.80 million	View	Listen
7/30/2014	Q214	($0.42)	($0.19)	$159.70 million	$191.70 million	View	N/A
5/1/2014	Q1 2014	($0.50)	($0.27)	$145.16 million	$151.60 million	View	N/A
2/26/2014	Q413	($0.35)	($0.11)	$146.07 million	$146.90 million	View	N/A
10/24/2013	Q313	($0.30)	($0.38)	$140.00 million	$136.90 million	View	N/A
7/25/2013	Q2 2013	($0.29)	($0.16)	$134.33 million	$136.80 million	View	N/A
4/25/2013	Q1 2013	($0.30)	($0.31)	$131.35 million	$127.90 million	View	N/A
2/21/2013	Q4 2012	($0.22)	($0.43)	$129.70 million	$130.96 million	View	N/A
10/25/2012		($0.20)	($0.04)			View	N/A
8/1/2012		($0.19)	($0.27)			View	N/A
4/26/2012		($0.15)	($0.21)			View	N/A
2/16/2012		($0.10)	($0.23)			View	N/A
10/27/2011		($0.10)	($0.16)			View	N/A
7/28/2011		($0.09)	($0.05)			View	N/A
4/28/2011		($0.10)	$0.14			View	N/A
2/17/2011		($0.02)	($0.11)			View	N/A
10/28/2010	Q3 2010	($0.02)	($0.03)			View	N/A
8/2/2010	Q2 2010	$0.02	($0.01)			View	N/A
4/29/2010	Q1 2010		$0.01			View	N/A
2/23/2010	Q4 2009		$0.05			View	N/A
10/28/2009	Q3 2009		$0.06			View	N/A
4/30/2009	Q1 2009	($0.12)	($0.13)			View	N/A
2/18/2009	Q4 2008	$0.24	$0.24			View	N/A
10/28/2008	Q3 2008	$0.03	$0.01			View	N/A
8/5/2008	Q2 2008	$0.02	$0.04			View	N/A
4/29/2008	Q1 2008	($0.04)	$0.02			View	N/A
2/26/2008	Q4 2007	$0.04	$0.03			View	N/A

(Earnings results data provided by Zacks Investment Research)

BioMarin Pharmaceutical (NASDAQ:BMRN) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

BioMarin Pharmaceutical (NASDAQ BMRN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.85%

Insider Trading History for BioMarin Pharmaceutical (NASDAQ:BMRN)

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical (NASDAQ BMRN) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/20/2018	Jean Jacques Bienaime	CEO	Sell	10,000	$83.65	$836,500.00	300,031
4/17/2018	V Bryan Lawlis	Director	Sell	3,750	$85.00	$318,750.00	18,610
4/2/2018	Henry J Fuchs	Insider	Sell	10,000	$80.12	$801,200.00	160,026
4/2/2018	Jeffrey Robert Ajer	EVP	Sell	2,119	$80.12	$169,774.28	52,914
3/29/2018	Jeffrey Robert Ajer	EVP	Sell	1,537	$79.69	$122,483.53	55,033
3/23/2018	George Eric Davis	EVP	Sell	3,350	$81.35	$272,522.50	87,989
3/21/2018	Jeffrey Robert Ajer	EVP	Sell	4,368	$83.90	$366,475.20	60,153
3/16/2018	George Eric Davis	EVP	Sell	3,818	$83.88	$320,253.84	94,634
3/15/2018	Jean Jacques Bienaime	CEO	Sell	15,000	$84.73	$1,270,950.00	279,674
3/9/2018	Jeffrey Robert Ajer	EVP	Sell	2,972	$82.39	$244,863.08	55,332
3/5/2018	George Eric Davis	EVP	Sell	2,105	$79.04	$166,379.20	90,089
2/15/2018	Jean Jacques Bienaime	CEO	Sell	10,000	$84.63	$846,300.00
2/1/2018	George Eric Davis	EVP	Sell	30,000	$90.66	$2,719,800.00	112,942
1/5/2018	Jean Jacques Bienaime	CEO	Sell	10,000	$90.32	$903,200.00	235,894
1/2/2018	Henry J. Fuchs	Insider	Sell	15,000	$89.23	$1,338,450.00
1/2/2018	V Bryan Lawlis	Director	Sell	3,750	$88.84	$333,150.00
12/29/2017	Jean Jacques Bienaime	CEO	Sell	20,000	$89.75	$1,795,000.00
12/29/2017	Jean Jacques Bienaime	CEO	Sell	10,000	$89.61	$896,100.00	226,494
12/14/2017	Elaine J Heron	Director	Sell	800	$88.90	$71,120.00	38,385
11/30/2017	George Eric Davis	EVP	Sell	1,200	$85.64	$102,768.00
9/28/2017	Robert Baffi	EVP	Sell	18,415	$92.43	$1,702,098.45	129,083
9/22/2017	Jeffrey Robert Ajer	EVP	Sell	3,521	$95.00	$334,495.00	49,299
9/15/2017	Henry J Fuchs	Insider	Sell	15,000	$90.50	$1,357,500.00	141,422
9/15/2017	V Bryan Lawlis	Director	Sell	3,750	$91.26	$342,225.00	19,660
6/23/2017	George Eric Davis	EVP	Sell	9,844	$96.60	$950,930.40	93,425
6/22/2017	Brian Mueller	SVP	Sell	2,671	$100.00	$267,100.00	15,556
6/19/2017	Henry J Fuchs	Insider	Sell	15,000	$90.00	$1,350,000.00	141,422
6/16/2017	V Bryan Lawlis	Director	Sell	3,750	$90.00	$337,500.00	19,660
6/7/2017	Jeffrey Robert Ajer	EVP	Sell	1,004	$89.61	$89,968.44	47,944
6/5/2017	George Eric Davis	EVP	Sell	9,471	$91.04	$862,239.84	74,342
6/5/2017	Jean Jacques Bienaime	CEO	Sell	10,000	$90.13	$901,300.00	238,564
5/24/2017	Jean Jacques Bienaime	CEO	Sell	5,000	$88.38	$441,900.00	238,564
5/17/2017	Jean Jacques Bienaime	CEO	Sell	5,000	$91.73	$458,650.00	238,564
5/8/2017	Brian Mueller	SVP	Sell	7,482	$91.87	$687,371.34	18,350
5/8/2017	Jean Jacques Bienaime	CEO	Sell	10,000	$96.09	$960,900.00	238,496
5/5/2017	George Eric Davis	EVP	Sell	2,500	$100.34	$250,850.00	85,251
5/2/2017	Jeffrey Robert Ajer	EVP	Sell	302	$96.74	$29,215.48	51,834
4/27/2017	Jean Jacques Bienaime	CEO	Sell	5,000	$95.72	$478,600.00	243,194
4/25/2017	Jean Jacques Bienaime	CEO	Sell	5,000	$94.00	$470,000.00	243,194
3/29/2017	Jeffrey Robert Ajer	EVP	Sell	3,890	$89.15	$346,793.50	51,532
3/16/2017	Daniel K Spiegelman	CFO	Sell	1,989	$91.96	$182,908.44	16,460
3/16/2017	George Eric Davis	EVP	Sell	2,238	$91.96	$205,806.48	75,967
3/16/2017	Jean Jacques Bienaime	CEO	Sell	10,000	$91.69	$916,900.00	211,364
3/10/2017	Jean Jacques Bienaime	CEO	Sell	11,000	$90.59	$996,490.00	212,364
3/7/2017	Jeffrey Robert Ajer	EVP	Sell	5,000	$90.56	$452,800.00	46,510
3/6/2017	Daniel K Spiegelman	CFO	Sell	2,303	$93.32	$214,915.96	20,761
3/6/2017	George Eric Davis	EVP	Sell	1,498	$93.32	$139,793.36	78,962
3/1/2017	Daniel K Spiegelman	CFO	Sell	35,000	$94.07	$3,292,450.00	60,347
3/1/2017	V Bryan Lawlis	Director	Sell	7,500	$95.00	$712,500.00	21,360
2/24/2017	Henry J Fuchs	Insider	Sell	15,000	$87.99	$1,319,850.00	128,442
1/26/2017	Jean Jacques Bienaime	CEO	Sell	10,000	$84.22	$842,200.00	175,682
1/11/2017	Jean Jacques Bienaime	CEO	Sell	8,000	$90.58	$724,640.00	174,682
1/9/2017	Daniel K Spiegelman	CFO	Sell	5,000	$90.00	$450,000.00	18,100
1/9/2017	Jean Jacques Bienaime	CEO	Sell	8,000	$88.49	$707,920.00	174,682
12/30/2016	Jean Jacques Bienaime	CEO	Sell	8,000	$83.60	$668,800.00	174,682
11/22/2016	Jean Jacques Bienaime	CEO	Sell	69,743	$85.69	$5,976,277.67
11/21/2016	Jean Jacques Bienaime	CEO	Sell	69,744	$87.56	$6,106,784.64
11/8/2016	Jean Jacques Bienaime	CEO	Sell	140,000	$82.67	$11,573,800.00	393,368
11/7/2016	Jean Jacques Bienaime	CEO	Sell	70,000	$82.52	$5,776,400.00	393,368
10/28/2016	Jean Jacques Bienaime	CEO	Sell	120,000	$81.30	$9,756,000.00	383,368
10/17/2016	Jean Jacques Bienaime	CEO	Sell	41,666	$84.39	$3,516,193.74	365,034
10/14/2016	Jean Jacques Bienaime	CEO	Sell	64,125	$86.96	$5,576,310.00	378,184
9/29/2016	Jean Jacques Bienaime	CEO	Sell	53,125	$93.65	$4,975,156.25	431,709
9/27/2016	Jeffrey Robert Ajer	EVP	Sell	18,467	$95.61	$1,765,629.87	41,342
9/16/2016	Jean Jacques Bienaime	CEO	Sell	137,368	$95.34	$13,096,665.12	421,161
8/26/2016	Henry J Fuchs	EVP	Sell	15,000	$95.06	$1,425,900.00	128,878
8/16/2016	Jean Jacques Bienaime	CEO	Sell	41,666	$91.49	$3,812,022.34	420,250
8/1/2016	Brian Mueller	VP	Sell	287	$100.00	$28,700.00	14,260
8/1/2016	Daniel K Spiegelman	CFO	Sell	4,000	$99.33	$397,320.00	42,944
8/1/2016	George Eric Davis	EVP	Sell	2,167	$100.00	$216,700.00	71,158
7/27/2016	V Bryan Lawlis	Director	Sell	1,100	$95.39	$104,929.00	14,960
7/22/2016	V Bryan Lawlis	Director	Sell	6,400	$95.01	$608,064.00	20,260
7/18/2016	Jean Jacques Bienaime	CEO	Sell	41,666	$92.72	$3,863,271.52	420,250
7/7/2016	George Eric Davis	EVP	Sell	2,167	$90.00	$195,030.00	72,836
6/20/2016	V Bryan Lawlis	Director	Sell	550	$82.77	$45,523.50	13,860
6/16/2016	Jean Jacques Bienaime	CEO	Sell	41,666	$80.55	$3,356,196.30	420,250
6/6/2016	Daniel K Spiegelman	CFO	Sell	1,649	$89.14	$146,991.86	46,944
5/31/2016	Daniel K Spiegelman	CFO	Sell	20,841	$89.88	$1,873,189.08	71,235
5/26/2016	Henry J Fuchs	EVP	Sell	15,000	$87.81	$1,317,150.00	130,914
5/23/2016	Daniel K Spiegelman	CFO	Sell	3,769	$87.07	$328,166.83	58,644
5/18/2016	Robert Baffi	EVP	Sell	5,000	$87.05	$435,250.00	130,386
5/10/2016	George Eric Davis	EVP	Sell	14,658	$85.11	$1,247,542.38	91,894
5/5/2016	Jean Jacques Bienaime	CEO	Sell	50,000	$80.15	$4,007,500.00	390,156
5/3/2016	Jeffrey Robert Ajer	EVP	Sell	415	$86.03	$35,702.45	63,487
5/2/2016	Jean Jacques Bienaime	CEO	Sell	36,500	$85.01	$3,102,865.00	395,635
3/14/2016	George Eric Davis	EVP	Sell	1,996	$86.21	$172,075.16	76,190
3/4/2016	Jeffrey Robert Ajer	SVP	Sell	1,255	$88.42	$110,967.10	48,137
3/2/2016	Daniel K Spiegelman	CFO	Sell	4,623	$86.12	$398,132.76	54,311
3/1/2016	Jean Jacques Bienaime	CEO	Sell	10,000	$84.28	$842,800.00	350,500
2/22/2016	Michael G Grey	Director	Sell	7,500	$80.00	$600,000.00	33,750
12/16/2015	George Eric Davis	SVP	Sell	1,362	$100.00	$136,200.00	66,156
11/30/2015	Jean Jacques Bienaime	CEO	Sell	1,000	$94.74	$94,740.00	228,754
11/16/2015	Daniel K. Spiegelman	CFO	Sell	20,000	$104.30	$2,086,000.00	28,229
11/16/2015	V Bryan Lawlis	Director	Sell	8,550	$106.90	$913,995.00	11,850
10/15/2015	Jean Jacques Bienaime	CEO	Sell	1,000	$108.24	$108,240.00	228,754
9/14/2015	Jean Jacques Bienaime	CEO	Sell	1,000	$131.43	$131,430.00	228,754
7/20/2015	Jeffrey Robert Ajer	SVP	Sell	3,000	$150.00	$450,000.00
7/7/2015	Jean Jacques Bienaime	CEO	Sell	1,500	$139.07	$208,605.00
6/5/2015	Daniel K Spiegelman	CFO	Sell	1,649	$122.30	$201,672.70
6/5/2015	Henry J Fuchs	EVP	Sell	1,864	$122.32	$228,004.48
6/4/2015	Jeffrey Robert Ajer	SVP	Sell	1,362	$122.35	$166,640.70
6/1/2015	Daniel K Spiegelman	CFO	Sell	5,523	$124.73	$688,883.79
6/1/2015	Jeffrey Robert Ajer	SVP	Sell	377	$123.76	$46,657.52
5/29/2015	Daniel K Spiegelman	CFO	Sell	1,578	$126.15	$199,064.70
5/26/2015	Jeffrey Robert Ajer	SVP	Sell	1,625	$126.55	$205,643.75
5/18/2015	Daniel K Spiegelman	CFO	Sell	2,059	$124.77	$256,901.43
5/18/2015	George Eric Davis	SVP	Sell	2,558	$125.26	$320,415.08
5/18/2015	Henry J Fuchs	EVP	Sell	1,864	$124.78	$232,589.92
5/13/2015	Henry J Fuchs	EVP	Sell	1,434	$121.37	$174,044.58
5/11/2015	Henry J Fuchs	EVP	Sell	2,869	$121.64	$348,985.16
3/17/2015	Jean Jacques Bienaime	CEO	Sell	2,000	$124.17	$248,340.00
3/16/2015	Henry J Fuchs	EVP	Sell	41,315	$123.57	$5,105,294.55
3/16/2015	Jean Jacques Bienaime	CEO	Sell	1,000	$123.48	$123,480.00
3/10/2015	Jean Jacques Bienaime	CEO	Sell	21,021	$112.39	$2,362,550.19
3/9/2015	Jean Jacques Bienaime	CEO	Sell	19,000	$112.13	$2,130,470.00
3/5/2015	Jean Jacques Bienaime	CEO	Sell	10,000	$113.70	$1,137,000.00
3/5/2015	Robert Baffi	EVP	Sell	14,051	$116.37	$1,635,114.87
3/4/2015	Jean Jacques Bienaime	CEO	Sell	13,916	$107.92	$1,501,814.72
3/3/2015	Jean Jacques Bienaime	CEO	Sell	5,000	$107.42	$537,100.00
3/2/2015	Daniel K Spiegelman	CFO	Sell	15,500	$107.00	$1,658,500.00
3/2/2015	George Eric Davis	SVP	Sell	23,000	$108.31	$2,491,130.00
3/2/2015	Jean Jacques Bienaime	CEO	Sell	5,000	$108.44	$542,200.00
1/9/2015	Jean Jacques Bienaime	CEO	Sell	2,000	$94.14	$188,280.00
12/24/2014	Jean Jacques Bienaime	CEO	Sell	5,000	$88.73	$443,650.00
12/10/2014	Jean Jacques Bienaime	CEO	Sell	2,000	$95.00	$190,000.00
12/4/2014	Alan Lewis	Director	Sell	7,500	$89.90	$674,250.00
12/2/2014	Brian Mueller	VP	Sell	11,950	$90.91	$1,086,374.50
11/25/2014	George Eric Davis	SVP	Sell	20,000	$89.75	$1,795,000.00
11/25/2014	Jean Jacques Bienaime	CEO	Sell	2,000	$90.00	$180,000.00
11/12/2014	Jean Jacques Bienaime	CEO	Sell	1,000	$81.51	$81,510.00
11/10/2014	Henry J Fuchs	EVP	Sell	20,000	$86.55	$1,731,000.00
11/10/2014	Jean Jacques Bienaime	CEO	Sell	4,000	$87.00	$348,000.00
11/3/2014	Jean Jacques Bienaime	CEO	Sell	3,000	$85.33	$255,990.00
11/3/2014	Jeffrey Robert Ajer	SVP	Sell	47	$83.54	$3,926.38
10/30/2014	Robert Baffi	EVP	Sell	75,425	$81.34	$6,135,069.50
10/24/2014	Jean Jacques Bienaime	CEO	Sell	2,000	$80.00	$160,000.00
9/19/2014	George Eric Davis	SVP	Sell	17,536	$69.75	$1,223,136.00
9/2/2014	Daniel K Spiegelman	CFO	Sell	16,000	$69.83	$1,117,280.00
8/20/2014	Jean Jacques Bienaime	CEO	Sell	5,000	$70.00	$350,000.00
8/5/2014	Henry J Fuchs	EVP	Sell	10,000	$65.00	$650,000.00
8/1/2014	Daniel K Spiegelman	CFO	Sell	2,229	$61.76	$137,663.04
7/2/2014	Daniel K Spiegelman	CFO	Sell	2,229	$64.00	$142,656.00
6/4/2014	Jean Jacques Bienaime	CEO	Sell	2,000	$61.20	$122,400.00
5/22/2014	Jean Jacques Bienaime	CEO	Sell	1,000	$56.88	$56,880.00	180,257
5/21/2014	Jean Jacques Bienaime	CEO	Sell	1,545	$56.19	$86,813.55	180,257
5/16/2014	Henry Fuchs	EVP	Sell	1,864	$56.86	$105,987.04	60,950
5/16/2014	Jeffrey Robert Ajer	SVP	Sell	1,004	$56.91	$57,137.64	20,980
5/16/2014	V Bryan Lawlis	Director	Sell	1,700	$56.87	$96,679.00	9,700
5/13/2014	Henry Fuchs	EVP	Sell	1,434	$58.23	$83,501.82	64,850
5/9/2014	Henry Fuchs	EVP	Sell	3,479	$57.91	$201,468.89	67,850
2/3/2014	Henry Fuchs	EVP	Sell	10,000	$67.70	$677,000.00	42,350
12/24/2013	Jean Jacques Bienaime	CEO	Sell	10,000	$68.71	$687,100.00
12/5/2013	Jean Jacques Bienaime	CEO	Sell	5,000	$69.70	$348,500.00
10/16/2013	Jean Jacques Bienaime	CEO	Sell	2,000	$67.73	$135,460.00
10/10/2013	Jean Jacques Bienaime	CEO	Sell	3,000	$66.76	$200,280.00
9/19/2013	Henry Fuchs	EVP	Sell	10,000	$80.19	$801,900.00	43,266
9/16/2013	Jean Jacques Bienaime	CEO	Sell	2,000	$73.08	$146,160.00
9/9/2013	Robert Baffi	EVP	Sell	20,000	$73.00	$1,460,000.00
9/5/2013	Henry J Fuchs	EVP	Sell	10,000	$70.00	$700,000.00
9/4/2013	Daniel K Spiegelman	CFO	Sell	9,000	$69.00	$621,000.00
8/15/2013	Jean Jacques Bienaime	CEO	Sell	1,000	$64.36	$64,360.00
7/1/2013	Daniel K Spiegelman	CFO	Sell	4,066	$59.78	$243,065.48
7/1/2013	Henry J Fuchs	EVP	Sell	10,000	$60.00	$600,000.00
6/3/2013	Henry J Fuchs	EVP	Sell	1,098	$58.32	$64,035.36
5/23/2013	Henry J Fuchs	EVP	Sell	20,609	$66.29	$1,366,170.61
5/22/2013	Mark Wood	VP	Sell	3,103	$67.12	$208,273.36
5/21/2013	Jean Jacques Bienaime	CEO	Sell	2,000	$64.14	$128,280.00
5/16/2013	Jean Jacques Bienaime	CEO	Sell	12,000	$67.90	$814,800.00
5/14/2013	Brian Mueller	VP	Sell	4,947	$70.35	$348,021.45
5/14/2013	George Eric Davis	SVP	Sell	20,000	$70.34	$1,406,800.00
5/14/2013	Jean Jacques Bienaime	CEO	Sell	15,000	$70.17	$1,052,550.00
5/13/2013	Jean Jacques Bienaime	CEO	Sell	15,800	$68.77	$1,086,566.00
5/13/2013	Jeffrey Robert Ajer	SVP	Sell	1,248	$69.26	$86,436.48
5/8/2013	Jean Jacques Bienaime	CEO	Sell	4,000	$65.87	$263,480.00
5/2/2013	Jean Jacques Bienaime	CEO	Sell	3,000	$64.99	$194,970.00
4/10/2013	Robert Baffi	EVP	Sell	20,000	$64.00	$1,280,000.00
3/22/2013	Mark Wood	VP	Sell	3,103	$60.21	$186,831.63
3/4/2013	George Eric Davis	SVP	Sell	4,000	$60.18	$240,720.00
2/22/2013	Mark Wood	VP	Sell	3,103	$55.22	$171,347.66
2/4/2013	Jean Jacques Bienaime	CEO	Sell	2,000	$55.77	$111,540.00
12/27/2012	Jean Jacques Bienaime	CEO	Sell	17,000	$48.37	$822,290.00
11/12/2012	George Eric Davis	SVP	Sell	99,075	$48.45	$4,800,183.75
9/4/2012	Henry J Fuchs	EVP	Sell	5,000	$37.76	$188,800.00
8/22/2012	Mark Wood	VP	Sell	2,665	$37.93	$101,083.45

(Data available from 1/1/2013 forward)

BioMarin Pharmaceutical (NASDAQ BMRN) News Headlines

Source:

Date	Headline
	BioMarin Pharmaceutical (BMRN) Releases FY18 Earnings Guidance www.americanbankingnews.com - April 25 at 5:32 PM
	How Financially Strong Is BioMarin Pharmaceutical Inc (NASDAQ:BMRN)? finance.yahoo.com - April 25 at 4:25 PM
	BioMarin Announces First Quarter 2018 Financial Results finance.yahoo.com - April 25 at 4:25 PM
	3 Charts That Suggest Biotech Stocks Are Headed Lower finance.yahoo.com - April 25 at 4:25 PM
	BioMarin Pharmaceutical (BMRN) Cut to "Hold" at Zacks Investment Research www.americanbankingnews.com - April 25 at 1:30 PM
	Insider Selling: BioMarin Pharmaceutical (BMRN) CEO Sells 10,000 Shares of Stock www.americanbankingnews.com - April 24 at 10:22 PM
	BioMarin Pharma (BMRN) Says NEJM Published Open-label Study Showing Brineura Reduced Rate of Clinical Decline of Children with CLN2 Disease www.streetinsider.com - April 24 at 4:19 PM
	What's in the Cards for BioMarin (BMRN) in Q1 Earnings? finance.yahoo.com - April 24 at 4:19 PM
	Chardan's Top Pick For 2018: Gene Therapy Firm Uniqure finance.yahoo.com - April 24 at 4:19 PM
	What's in the Cards for BioMarin (BMRN) in Q1 Earnings? finance.yahoo.com - April 24 at 4:19 PM
	New England Journal of Medicine Published Open-label Study Showing Brineura® (cerliponase alfa) Reduced the Rate of Clinical Decline of Children with CLN2 Disease, a Form of Batten Disease finance.yahoo.com - April 24 at 4:19 PM
	BioMarin Pharmaceutical (BMRN) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - April 24 at 12:47 PM
	BioMarin Pharmaceutical (BMRN) Rating Lowered to Strong Sell at BidaskClub www.americanbankingnews.com - April 24 at 11:02 AM
	BioMarin Pharmaceutical (BMRN) Director Sells $318,750.00 in Stock www.americanbankingnews.com - April 19 at 10:10 PM
	BioMarin Pharmaceutical (BMRN) Set to Announce Quarterly Earnings on Wednesday www.americanbankingnews.com - April 19 at 8:46 AM
	BioMarin Pharmaceutical's (BMRN) "Outperform" Rating Reiterated at BMO Capital Markets www.americanbankingnews.com - April 18 at 2:28 PM
	4 Red-Hot Biotech Stocks to Buy Before Earnings 247wallst.com - April 18 at 9:55 AM
	BioMarin to Host First Quarter 2018 Financial Results Conference Call and Webcast on Wednesday, April 25 at 4:30pm ET finance.yahoo.com - April 18 at 9:55 AM
	BioMarin Pharmaceutical (BMRN) Raised to "Strong-Buy" at Zacks Investment Research www.americanbankingnews.com - April 17 at 10:55 PM
	ValuEngine Downgrades BioMarin Pharmaceutical (BMRN) to Sell www.americanbankingnews.com - April 17 at 10:55 PM
	What Analysts Recommend for CymaBay Therapeutics finance.yahoo.com - April 17 at 9:44 AM
	BioMarin Pharmaceutical (BMRN) Downgraded to "Sell" at BidaskClub www.americanbankingnews.com - April 16 at 9:16 PM
	Why 4 Top Biotech Stocks May Be the Next Takeover Targets 247wallst.com - April 16 at 9:45 AM
	The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte finance.yahoo.com - April 16 at 9:45 AM
	BioMarin Pharmaceutical (BMRN) Coverage Initiated at Sanford C. Bernstein www.americanbankingnews.com - April 15 at 3:59 PM
	BioMarin Pharmaceutical (BMRN) Earns Buy Rating from Deutsche Bank www.americanbankingnews.com - April 13 at 12:59 PM
	Today’s Research Reports on Trending Tickers: Array BioPharma and BioMarin Pharmaceutical finance.yahoo.com - April 13 at 9:54 AM
	Did BioMarin Pharmaceutical Inc’s (NASDAQ:BMRN) Earnings Growth Outperform The Industry? finance.yahoo.com - April 13 at 9:54 AM
	$349.42 Million in Sales Expected for BioMarin Pharmaceutical (BMRN) This Quarter www.americanbankingnews.com - April 13 at 4:08 AM
	Deutsche Bank Reaffirms "Buy" Rating for BioMarin Pharmaceutical (BMRN) www.americanbankingnews.com - April 12 at 3:58 PM
	Zacks: Analysts Expect BioMarin Pharmaceutical Inc. (BMRN) Will Post Earnings of $0.13 Per Share www.americanbankingnews.com - April 11 at 8:23 AM
	BioMarin Pharmaceutical (BMRN) Earns "Buy" Rating from Jefferies Group www.americanbankingnews.com - April 8 at 8:06 PM
	BioMarin Pharmaceutical (BMRN) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - April 7 at 11:47 AM
	Catalyst (CPRX) Up on New Drug Application for Firdapse finance.yahoo.com - April 5 at 4:22 PM
	BioMarin Pharmaceutical Inc. (BMRN) Receives Consensus Recommendation of "Buy" from Analysts www.americanbankingnews.com - April 5 at 3:52 PM
	BioMarin Pharmaceutical (BMRN) PT Set at $130.00 by JPMorgan Chase www.americanbankingnews.com - April 4 at 4:42 PM
	BioMarin Pharmaceutical Inc. (BMRN) EVP Sells $169,774.28 in Stock www.americanbankingnews.com - April 3 at 10:27 PM
	BioMarin Pharmaceutical Inc. (BMRN) Insider Henry J. Fuchs Sells 10,000 Shares www.americanbankingnews.com - April 3 at 10:12 PM
	BioMarin Pharmaceutical’s Drugs in 4Q17 and Fiscal 2017 finance.yahoo.com - April 3 at 4:31 PM
	Jeffrey Robert Ajer Sells 1,537 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock www.americanbankingnews.com - March 30 at 10:14 PM
	Roche Hashes Out Details Of Patient Deaths In Hemophilia Drug finance.yahoo.com - March 29 at 4:24 PM
	BioMarin Pharmaceutical (BMRN) Rating Reiterated by Credit Suisse Group www.americanbankingnews.com - March 29 at 12:11 PM
	BioMarin Pharma (BMRN) Says EMS Accepted its MAA for Pegvaliase for Treatment of Phenylketonuria www.streetinsider.com - March 29 at 9:58 AM
	European Medicines Agency (EMA) Accepts BioMarin's Marketing Application for Pegvaliase MAA for Treatment of Phenylketonuria (PKU) finance.yahoo.com - March 28 at 4:20 PM
	BioMarin Pharmaceutical (BMRN) Lifted to "Buy" at Zacks Investment Research www.americanbankingnews.com - March 28 at 2:06 PM
	Insider Selling: BioMarin Pharmaceutical Inc. (BMRN) EVP Sells 3,350 Shares of Stock www.americanbankingnews.com - March 27 at 10:32 PM
	BioMarin Pharmaceutical Inc. (BMRN) Expected to Announce Quarterly Sales of $348.04 Million www.americanbankingnews.com - March 27 at 5:56 AM
	A Look at Ionis’s Key Revenue Drivers in 4Q17 finance.yahoo.com - March 26 at 4:29 PM
	Apache (APA) Up 7% Since Earnings Report: Can It Continue? www.zacks.com - March 26 at 10:31 AM
	BioMarin Pharmaceutical (BMRN) Down 3.1% Since Earnings Report: Can It Rebound? finance.yahoo.com - March 26 at 10:31 AM

BioMarin Pharmaceutical (NASDAQ:BMRN) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

BioMarin Pharmaceutical (NASDAQ:BMRN) Income Statement, Balance Sheet and Cash Flow Statement

BioMarin Pharmaceutical (NASDAQ BMRN) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff